Navigation Links
Recently Approved Onglyza Is Covered by 44 Percent of Commercial Health Plans But Less Than One Percent of Medicare Plans for The Treatment of Type 2 Diabetes
Date:10/13/2009

NASHVILLE, Tenn. and GLEN ROCK, N.J., Oct. 13 /PRNewswire/ -- HealthLeaders-InterStudy and Fingertip Formulary find that Bristol-Myers Squibb/AstraZeneca's Onglyza is covered by 44 percent of commercial health plans but less than one percent of Medicare plans. According to the Formulary Forum report entitled Formulary Advantages in Type 2 Diabetes: Impact of Current and Future DPP-IV Inhibitors and GLP-1 Analogues on Advantaged Reimbursement Status for Key Brands, among plans that have Onglyza on formulary, the majority have placed the drug on Tier 3.

The three-tier open formulary is the most common formulary design in the U.S., therefore the positioning of Onglyza as a primarily Tier 3 benefit is consistent with survey findings that show 40 percent of surveyed pharmacy directors say they cover emerging agents, including Onglyza which was approved for the treatment of Type 2 diabetes in July, on their highest tier until they can complete an internal review.

"Large plans have most rapidly added Onglyza to their formularies but mostly as a Tier 3 benefit, likely as a default option until an internal review can be conducted and they can determine whether the drug should be upgraded to Tier 2," said Michael Malecki, Ph.D., product manager for Formulary Forum. "Our survey found that nearly three-quarters of surveyed pharmacy directors from large plans say they expect their managed care organization to review emerging therapies within six months of FDA approval, so we expect the story of Onglyza's coverage to evolve over the coming months."

About the Report

Formulary Advantages in Type 2 Diabetes: Impact of Current and Future DPP-IV Inhibitors and GLP-1 Analogues on Advantaged Reimbursement Status for Key Brands is based on a survey of 50 pharmacy directors who control national, regional and state-level managed care organizations. Answers were segmented by type of plan to illustrate variances in strategy by size of plan.

About Fingertip Formulary

Fingertip Formulary (www.FingertipFormulary.com), the leading provider of access to and insight into formulary data in the United States, offers comprehensive formulary data covering commercial, Medicaid, Medicare and PBM plans, among others. Fingertip Formulary is a Decision Resources, Inc. company.

About HealthLeaders-InterStudy

HealthLeaders-InterStudy, a Decision Resources, Inc. company, is the authoritative source for managed care data, analysis and news. For more information, please visit www.HL-ISY.com.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Both HealthLeaders-InterStudy and Fingertip Formulary are Decision Resources, Inc. companies. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Lisa Osgood                         Elizabeth Marshall
    HealthLeaders-InterStudy            Decision Resources, Inc.
    781-296-2606                        781-296-2563
    losgood@hl-isy.com                  emarshall@dresources.com

SOURCE HealthLeaders-InterStudy


'/>"/>
SOURCE HealthLeaders-InterStudy
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. ChemoCentryx Demonstrates Recently Discovered Chemokine Receptor CXCR7 is Essential in Tumor Growth
2. National Stem Cell Holding in Final Stage Negotiations for Exclusive Licensing of its Recently Discovered Biomaterial for Anti-Aging Applications
3. DelSite Nasal Powder Technology Could Reduce Recently Reported Waste in Federal Vaccine Program
4. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
5. MedImmune Strengthens Key Leadership Functions to Further Support Recently Expanded, Rapidly Advancing Product Portfolio
6. Alseres Pharmaceuticals, Inc. Complies with NASDAQ Rule Regarding Recently Filed 10-K
7. Accredited Construct Specific PCR Test for Recently Detected Unapproved GM Flax/Linseed FP967/CDC Triffid Available Through Genetic ID
8. Shires ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome
9. Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM)
10. Healthcare Announced That an Overwhelming Majority of its Shareholders Approved the NexGen Biofuels Transaction
11. Bystolic(TM), a Novel Beta Blocker, is Now Approved by the FDA for the Treatment of Hypertension
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers use ... 6000i models are higher end machines that use the more unconventional z-dimension of 20mm. ... from the bottom of the cuvette holder. , FireflySci has developed several Agilent ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
(Date:6/23/2016)... NEW YORK , June, 23, 2016  The ... students to envision new ways to harness living systems ... of Modern Art (MoMA) in New York ... more than 130 participating students, showcased projects at MoMA,s ... included Paola Antonelli , MoMA,s senior curator of ...
(Date:6/23/2016)... Ky. , June 23, 2016 ... two Phase 1 clinical trials of its complement ... placebo-controlled, single and multiple ascending dose studies designed ... pharmacodynamics (PD) of subcutaneous injection in healthy adult ... subcutaneously (SC) either as a single dose (ranging ...
Breaking Biology Technology:
(Date:5/24/2016)... patient care by providing unparalleled technology to leaders of the medical imaging industry.  As ... added to the range of products distributed by Ampronix. Photo - ... ... ... ...
(Date:5/16/2016)... 16, 2016   EyeLock LLC , a market ... opening of an IoT Center of Excellence in ... the development of embedded iris biometric applications. ... convenience and security with unmatched biometric accuracy, making it ... from DNA. EyeLock,s platform uses video technology to deliver ...
(Date:5/9/2016)... May 9, 2016 Elevay is ... to expanding freedom for high net worth professionals seeking ... today,s globally connected world, there is still no substitute ... ever duplicate sealing your deal with a firm handshake. ... by taking advantage of citizenship via investment programs like ...
Breaking Biology News(10 mins):